First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 1.30B |
| Revenue (ttm) | n/a |
| Net Income | -160.30M |
| EPS | -4.53 |
| Shares Out | 35.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 495,670 |
| Open | 35.01 |
| Previous Close | 34.46 |
| Day's Range | 35.00 - 36.53 |
| 52-Week Range | 14.72 - 49.91 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 74.17 (+103.21%) |
| Est. Earnings | Nov 12, 2026 |
About TRAX
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TRAX stock is "Strong Buy." The 12-month stock price target is $74.17, which is an increase of 103.21% from the latest price.
News
First Tracks Biotherapeutics announces $200M private placement
First Tracks Biotherapeutics (TRAX) announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in…
First Tracks Biotherapeutics Announces $200 Million Private Placement
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways imp...
First Tracks Biotherapeutics price target raised to $70 from $65 at Evercore ISI
Evercore ISI raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $70 from $65 and keeps an Outperform rating on the shares.
First Tracks Biotherapeutics price target raised to $60 from $50 at Canaccord
Canaccord raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $60 from $50 and keeps a Buy rating on the shares. The firm updated ts model after the…
First Tracks Biotherapeutics price target raised to $70 from $62 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $70 from $62 and keeps an Overweight rating on the shares. The firm believes…
First Tracks Biotherapeutics Transcript: Study result
In phase Ib celiac cohort one, ANB033 significantly protected intestinal histology and prevented gluten-challenge symptom increases, with a favorable safety profile. Cohort two results are expected in Q1 2027; late-stage development is anticipated to begin in 2027.
First Tracks Biotherapeutics Press release: Study result
First Tracks Biotherapeutics issued a press release on October 12, 2026, disclosing material business information to investors.
First Tracks Biotherapeutics Slides: Study result
First Tracks Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
First Tracks Biotherapeutics reports results from Cohort 1 of ANB033 trial
First Tracks Biotherapeutics (TRAX) announced top-line results from Cohort 1 of ANB033’s Phase 1b trial in celiac disease, or CeD. ANB033, an investigational, subcutaneously administered CD122 antagon...
First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo
Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps an Overweight rating on the shares. With Teva (TEVA) and Argenx (ARGX)…
First Tracks Biotherapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $50 price target The firm’s investment thesis is heavily concentrated in ANB033, which represents roughly 95% ...
First Tracks Biotherapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $50 price target
First Tracks Biotherapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of First Tracks Biotherapeutics (TRAX) with an Outperform rating and $65 price target The firm sees a “very high” probability of success on the upcoming gluten…
First Tracks Biotherapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $100 price target The firm has “high conviction” in the company’s lead asset ANB033, citing its potential…
First Tracks Biotherapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expected over the next year, with plans for further indication expansion and a focus on differentiation in a competitive landscape.
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways imp...
First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)
“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. W...
First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays
Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $48 and keeps an Overweight rating on the shares post the Q2 report. The company reiterates…
First Tracks price target raised to $57 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $44 and keeps a Buy rating on the shares following the Q2 report. The firm…
First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler
Piper Sandler raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $95 from $54 based on competitor clinical validation of anti-CD122 mechanism of action, while keeping an Overweig...
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways imp...
First Tracks Biotherapeutics Earnings release: Q2 2026
First Tracks Biotherapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
First Tracks Biotherapeutics Quarterly report: Q2 2026
First Tracks Biotherapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
First Tracks Biotherapeutics management to meet with Piper Sandler
Meeting to be held on August 17-18 hosted by Piper Sandler.
First Tracks Biotherapeutics price target raised to $65 from $45 at UBS
UBS raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $45 and keeps a Buy rating on the shares.